% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 Apr 24, 2013 7:21 PM Flag

    Selumetinib abstract titles at ASCO 2013


    Abstract #CRA9003
    2:15 PM - 2:30 PM
    Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
    Richard D. Carvajal, MD

    Abstract #9004
    2:30 PM - 2:45 PM
    Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma.
    Mark R. Middleton, PhD, FRCP


    Abstract #9068
    DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.
    Avinash Gupta, MBBS BSc MRCP

    Abstract #TPS4145
    SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy.
    Vincent M. Chung, MD

    Abstract #3587
    The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
    Howard S. Hochster, MD

    Abstract #8026
    Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
    Corey A. Carter, MD
    Poster Board: #15

    Abstract #4014
    Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
    Andrew H. Ko, MD
    Poster Board: #6

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.24+0.07(+2.21%)Aug 26 4:00 PMEDT